Health Ministry to prepare National Action Plan on AMR 2.0
Convergent action on AMR identified as an important area of intervention
Convergent action on AMR identified as an important area of intervention
Urges Innovators to produce quality products that can be deployed at scale
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Construction will begin this year with the new capacity anticipated by 2025
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated